Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Pharm Compd ; 21(5): 426-429, 2017.
Article in English | MEDLINE | ID: mdl-29216619

ABSTRACT

The stability of dalteparin 1,000 units/mL in 0.9% sodium chloride for injection stored in polypropylene syringes under refrigeration was examined. Dalteparin 1,000-units/mL syringes were prepared by adding 9 mL of 0.9% sodium chloride for injection to 1 mL of dalteparin sodium 10,000 unit/mL from commercial single-use syringes. Compounded solutions in 0.5-mL aliquots were transferred to 1-mL polypropylene syringes and sealed with a Luer lock tip cap and stored at refrigerated temperatures (2°C to 8°C) with ambient fluorescent light exposure. Syringes from three batches of dalteparin 1,000 units/mL were potency tested in duplicate by a stability-indicating high-performance liquid chromatography assay using a 0.5-mL sample at specified intervals. Visual and pH testing were performed on each batch. Samples were visually inspected for container integrity, color, and clarity. Samples for pH testing were prepared using a 1:1 dilution of dalteparin 1,000 units/mL in sterile water for injection and underwent duplicate analysis at each time point. High-performance liquid chromatography analyses showed a remaining percent of the initial dalteparin content at day 30 of 94.88% ± 2.11%. Samples remained colorless and clear with no signs of container compromise and no visual particulate matter at each time point. Throughout the 30-day study period, pH values remained within 0.3-pH units from the initial value of 5.84. Dalteparin 1,000 unit/mL in 0.9% sodium chloride for injection, packaged in 1-mL polypropylene syringes was stable for at least 30 days while stored at refrigerated conditions with ambient fluorescent light exposure.


Subject(s)
Dalteparin/chemistry , Chromatography, High Pressure Liquid , Dalteparin/analysis , Dalteparin/pharmacology , Drug Stability , Factor Xa Inhibitors/pharmacology , Hydrogen-Ion Concentration , Injections , Polypropylenes , Sodium Chloride , Syringes
2.
Int J Pharm Compd ; 21(2): 150-153, 2017.
Article in English | MEDLINE | ID: mdl-28346210

ABSTRACT

The stability of alprostadil diluted in 0.9% sodium chloride stored in polyvinyl chloride (VIAFLEX) containers at refrigerated temperature, protected from light, is reported. Five solutions of alprostadil 11 mcg/mL were prepared in 250 mL 0.9% sodium chloride polyvinyl chloride (PL146) containers. The final concentration of alcohol was 2%. Samples were stored under refrigeration (2°C to 8°C) with protection from light. Two containers were submitted for potency testing and analyzed in duplicate with the stability-indicating high-performance liquid chromatography assay at specific time points over 14 days. Three containers were submitted for pH and visual testing at specific time points over 14 days. Stability was defined as retention of 90% to 110% of initial alprostadil concentration, with maintenance of the original clear, colorless, and visually particulate-free solution. Study results reported retention of 90% to 110% initial alprostadil concentration at all time points through day 10. One sample exceeded 110% potency at day 14. pH values did not change appreciably over the 14 days. There were no color changes or particle formation detected in the solutions over the study period. This study concluded that during refrigerated, light-protected storage in polyvinyl chloride (VIAFLEX) containers, a commercial alcohol-containing alprostadil formulation diluted to 11 mcg/mL with 0.9% sodium chloride 250 mL was stable for 10 days.


Subject(s)
Alprostadil/chemistry , Drug Packaging , Excipients/chemistry , Platelet Aggregation Inhibitors/chemistry , Polyvinyl Chloride/chemistry , Sodium Chloride/chemistry , Vasodilator Agents/chemistry , Alprostadil/pharmacology , Alprostadil/radiation effects , Chromatography, High Pressure Liquid , Cold Temperature , Drug Compounding , Drug Stability , Drug Storage , Hydrogen-Ion Concentration , Isotonic Solutions , Light , Platelet Aggregation Inhibitors/pharmacology , Platelet Aggregation Inhibitors/radiation effects , Sodium Chloride/radiation effects , Time Factors , Vasodilator Agents/pharmacology , Vasodilator Agents/radiation effects
SELECTION OF CITATIONS
SEARCH DETAIL
...